Technetium-99m Nanoradiopharmaceuticals for Decreasing the Patients Internal Dose

Radiopharmaceuticals are the key tools of medicine in general and nuclear medicine in particular, both in the context of diagnosis and therapy. The radiopharmaceutical chemistry demonstrates its capability to contribute to the industrial development of new drugs. Nanomaterials, due to their unique capabilities and purported minimal side effects in treating variety of sicknesses, nanomaterials have a wide range of biomedical applications. The emergence of nanomaterials science and radiopharmacy, which is creation and utilization of materials at the nanometer scale, has been a great influence on radiopharmaceutical industry. Growth of nuclear medicine has been due mainly to the availability of Technetium-99m (Tc-99m) radiopharmaceuticals; this single isotope is used in over 80% of all diagnostic procedures. Each year, roughly 25 million procedures are carried out with Tc-99m radiopharmaceuticals, and this figure is projected to grow at a rate of about 15% per annum. Now a days, various colloids of nano size Tc-99m are used for diagnosis. In this research, the effect of nanoTc-99m nanoradiomedicine on the internal dose of patients are studied.